{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:02:12Z","timestamp":1790784132084,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaip.2025.04.042","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:10:51Z","timestamp":1747048251000},"page":"1901-1910.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors"],"prefix":"10.1016","volume":"13","author":[{"given":"Masahiro","family":"Kamata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan I.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.04.042_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3122\/jabfm.2019.02.180225","article-title":"The burden of childhood atopic dermatitis in the primary care setting: a report from the meta-LARC consortium","volume":"32","author":"Al-Naqeeb","year":"2019","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaad.2018.05.1241","article-title":"A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/pde.14971","article-title":"Differences between pediatric and adult atopic dermatitis","volume":"39","author":"Ram\u00edrez-Mar\u00edn","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.det.2024.04.005","article-title":"Long-term impact of atopic dermatitis on quality of life","volume":"42","author":"Fitzmaurice","year":"2024","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2025.04.042_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.anai.2023.09.009","article-title":"Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives","volume":"132","author":"Stefanovic","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.15730","article-title":"Current treatments for atopic dermatitis in Japan","volume":"48","author":"Miyano","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.042_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2017.10.002","article-title":"Barrier dysfunction in the skin allergy","volume":"67","author":"Egawa","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.04.042_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.04.042_bib14","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2025.04.042_bib17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jaip.2025.04.042_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1203475420982553","article-title":"Inhibition of IL-13: a new pathway for atopic dermatitis","volume":"25","author":"Ratnarajah","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaip.2025.04.042_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib20","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Gon\u00e7alves","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaip.2025.04.042_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/JAA.S211032","article-title":"Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis","volume":"13","author":"Loh","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6887","article-title":"IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis","volume":"8","author":"Fassett","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib23","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.042_bib25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/bjd\/ljae458","article-title":"Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study","volume":"192","author":"Igarashi","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaip.2025.04.042_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2025.04.042_bib28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaip.2025.04.042_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.jaip.2025.04.042_bib30","first-page":"927","article-title":"Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis","volume":"11","author":"Pereyra-Rodriguez","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jaip.2025.04.042_bib59","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/1346-8138.17626","article-title":"Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events","volume":"52","author":"Sugiyama","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib113","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/jcm14093026","article-title":"Cutaneous adverse events following nemolizumab administration: a review","volume":"14","author":"Mima","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","article-title":"Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.042_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib34","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update","volume":"160","author":"Drucker","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials","volume":"24","author":"Stein","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2025.04.042_bib41","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib42","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib44","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib45","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib46","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/jdv.18377","article-title":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances","volume":"36","author":"St\u00e4nder","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.04.042_bib47","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00403-024-03225-4","article-title":"Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study","volume":"316","author":"David","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaip.2025.04.042_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2023.01.043","article-title":"Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: a review","volume":"89","author":"Shi","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s13555-024-01143-x","article-title":"Matching-adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis","volume":"14","author":"Torres","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2025.04.042_bib53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/derm.2023.0030","article-title":"First Short-Term Effectiveness and Security Data of Tralokinumab in Severe Atopic Dermatitis\u00ae in real clinical practice","volume":"35","author":"Garc\u00eda Castro","year":"2024","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2025.04.042_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2216815","article-title":"Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaip.2025.04.042_bib55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ced\/llad038","article-title":"Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice","volume":"48","author":"Schl\u00f6sser","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2285243","article-title":"Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience","volume":"34","author":"Ferrucci","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaip.2025.04.042_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2025.04.042_bib58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1684\/ejd.2023.4566","article-title":"Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis","volume":"33","author":"Kamada","year":"2023","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib61","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/1346-8138.16879","article-title":"Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib","volume":"50","author":"Hagino","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2025.04.042_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200866","article-title":"Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial","volume":"34","author":"Flohr","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaip.2025.04.042_bib64","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.04.042_bib65","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-023-01071-2","article-title":"Safety and efficacy of upadacitinib for atopic dermatitis in Japan: analysis of the 3-year phase 3 rising up study","volume":"14","author":"Katoh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2025.04.042_bib67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2411834","article-title":"Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years","volume":"35","author":"Wollenberg","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaip.2025.04.042_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaip.2025.04.042_bib70","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.36849\/JDD.7187","article-title":"JAK inhibitor safety compared to traditional systemic immunosuppressive therapies","volume":"21","author":"Daniele","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib72","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib73","doi-asserted-by":"crossref","first-page":"e1283","DOI":"10.1111\/jdv.19269","article-title":"First update of the living European guideline (EuroGuiDerm) on atopic eczema","volume":"37","author":"Wollenberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.04.042_bib74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/17843286.2023.2285576","article-title":"Belgian atopic dermatitis guidelines","volume":"79","author":"Lapeere","year":"2024","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaip.2025.04.042_bib75","first-page":"223","volume":"159","author":"Argenziano","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.jaip.2025.04.042_bib76","first-page":"251","volume":"159","author":"Argenziano","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.jaip.2025.04.042_bib77","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/1346-8138.17544","article-title":"English version of clinical practice guidelines for the management of atopic dermatitis 2024","volume":"52","author":"Saeki","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib78","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.042_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"Torrelo","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib80","first-page":"e311","article-title":"English version of Japanese guidance for biologics in treating atopic dermatitis","volume":"50","author":"Saeki","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib81","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib82","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib83","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/jdv.19391","article-title":"Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.04.042_bib84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/bjd\/ljac057","article-title":"Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3","volume":"188","author":"Reich","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib85","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","article-title":"Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis","volume":"13","author":"Cork","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2025.04.042_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib88","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.042_bib89","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.alit.2024.04.006","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Ebisawa","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.04.042_bib90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.18565","article-title":"Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials","volume":"183","author":"Katoh","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib91","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105121","article-title":"Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review","volume":"103","author":"Park","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaip.2025.04.042_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12219","article-title":"The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis","volume":"13","author":"Spekhorst","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","article-title":"Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis","volume":"155","author":"Beck","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib95","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib96","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/derm.2024.0323","article-title":"Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: a 24-week real-world study","volume":"36","author":"Hagino","year":"2025","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2025.04.042_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.07.637","article-title":"53143 Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab","volume":"91","author":"Guttman-Yassky","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365544","article-title":"Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks","volume":"15","author":"Hagino","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/1346-8138.17173","article-title":"Real-world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood","volume":"51","author":"Uchiyama","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.16763","article-title":"Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"50","author":"Hagino","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib102","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14178","article-title":"Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: results of the BioDay registry","volume":"35","author":"van der Rijst","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib104","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","article-title":"Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study","volume":"91","author":"Lin","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2023.03.008","article-title":"Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy","volume":"152","author":"Yamamoto-Hanada","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.042_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12381","article-title":"Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients","volume":"14","author":"van der Rijst","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.04.042_bib107","article-title":"34312 Treatment with amlitelimab (KY1005, SAR445229): a novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis","volume":"87","author":"Weidinger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.04.042_bib108","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s12325-023-02755-z","article-title":"Summary of research: an anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"41","author":"Guttman-Yassky","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.04.042_bib109","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2025.04.042_bib110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14728214.2024.2345643","article-title":"Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials","volume":"29","author":"Obed","year":"2024","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jaip.2025.04.042_bib111","first-page":"77","article-title":"GB12-09, a bispecific antibody targeting IL4R\u03b1 and IL31R\u03b1 for atopic dermatitis therapy","volume":"7","author":"Deng","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.jaip.2025.04.042_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2024.100258","article-title":"A bispecific, tetravalent antibody targeting inflammatory and pruritogenic pathways in atopic dermatitis","volume":"4","author":"Tietz","year":"2024","journal-title":"JID Innov"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825004118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:53:59Z","timestamp":1778853239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825004118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":112,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2213219825004118"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.042","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}